Week 3 of Wegovy treatment marks an important early milestone in your weight management journey. At this stage, most patients remain on the 0.25 mg starting dose of semaglutide, allowing the body to adjust gradually before dose escalation begins. Whilst significant weight loss is not expected this early, subtle appetite changes and early side effects are common. Understanding what to expect during week 3 of Wegovy — including how the medication works, how to manage gastrointestinal symptoms, and how to support your progress with lifestyle changes — can help you stay on track and use the treatment safely and effectively.

What to Expect During Week 3 of Wegovy Treatment

In week 3, patients remain on the 0.25 mg starting dose; modest appetite reduction may begin, but significant weight loss is not expected at this early stage.

By week 3 of Wegovy (semaglutide) treatment, most patients are still in the initial dose titration phase, receiving the starting dose of 0.25 mg once weekly. This early stage is primarily about allowing your body to adjust to the medication rather than achieving maximum weight loss. It is important to set realistic expectations: significant weight reduction is unlikely at this point, and that is entirely normal.

Many patients begin to notice subtle changes during week 3, including a modest reduction in appetite and a feeling of fullness after smaller meals. Some individuals report that food cravings — particularly for high-calorie or ultra-processed foods — begin to diminish. These early signals suggest the medication is starting to interact with the body's appetite-regulating systems, even at the lowest dose.

Emotionally, week 3 can feel like a period of adjustment. Some patients feel encouraged by early changes, whilst others may feel frustrated if weight loss has not yet begun. It is worth noting that the titration schedule is designed with patient safety and tolerability in mind, not speed. Staying consistent with your weekly injection schedule and maintaining open communication with your prescribing clinician or pharmacist is strongly advised during this period.

Importantly, Wegovy must not be used at the same time as any other GLP-1 receptor agonist (such as liraglutide or dulaglutide) or any other semaglutide-containing medicine (such as Ozempic or Rybelsus). If you are currently taking any of these medicines, discuss this with your prescribing clinician before starting Wegovy. NHS access to Wegovy is currently through specialist weight management services for eligible adults — further details are provided in the dosing and availability section below.

Common Side Effects at This Stage and How to Manage Them

Nausea, bloating, diarrhoea, and constipation are the most common side effects in week 3; eating smaller meals, staying hydrated, and rotating injection sites can help manage symptoms.

Gastrointestinal side effects are the most frequently reported adverse effects during the early weeks of Wegovy treatment, including week 3. These commonly include:

• Nausea — often the most reported symptom, typically mild to moderate

• Vomiting — less common but possible, particularly after eating too quickly or too much

• Diarrhoea or constipation — bowel habit changes are frequently noted

• Bloating and indigestion — a sensation of fullness or discomfort after meals

• Fatigue — some patients report low energy levels in the early weeks

These effects are generally transient and tend to improve as the body adapts to the medication. To manage nausea, it is advisable to eat smaller, more frequent meals, avoid fatty or spicy foods, and remain upright for at least 30 minutes after eating.

Staying well hydrated is important, particularly if you are experiencing diarrhoea or vomiting. Aim for pale-yellow urine as a guide to adequate hydration; if you have heart or kidney conditions, follow your clinician's specific advice on fluid intake. Significant vomiting or diarrhoea can lead to dehydration and, in some cases, may affect kidney function. Seek medical attention promptly if you are unable to keep fluids down, feel dizzy or faint, notice very dark urine, or are passing much less urine than usual.

Gallbladder problems, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have been reported with semaglutide. Contact your GP or prescribing clinician promptly if you develop persistent pain in the upper right side of your abdomen, fever, or yellowing of the skin or eyes (jaundice).

Injection site reactions — such as redness, itching, or mild swelling — may also occur. Rotating injection sites (abdomen, thigh, or upper arm) with each weekly dose can help minimise localised discomfort.

If you have type 2 diabetes and are also taking insulin or a sulfonylurea (such as glibenclamide or gliclazide), be aware that Wegovy may increase the risk of low blood sugar (hypoglycaemia). Discuss whether your diabetes medication doses need adjusting with your prescribing clinician or diabetes team.

Contact your GP, prescribing clinician, or call 999/111 if you experience:

• Severe or persistent vomiting or abdominal pain

• Signs of pancreatitis: severe upper abdominal pain, which may radiate to the back, with or without vomiting — this requires urgent medical assessment

• Symptoms of a serious allergic reaction: rash, swelling of the face, lips, tongue or throat, or difficulty breathing

These are rare but important safety signals, as outlined in the Wegovy Summary of Product Characteristics (SmPC) approved by the MHRA.

If you think you have experienced a side effect from Wegovy, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Reporting helps the MHRA monitor the safety of medicines in the UK.

How Wegovy Works in the Body During the Early Weeks

Semaglutide mimics the GLP-1 hormone to reduce appetite via brain receptors and slow gastric emptying, with these effects present but intentionally modest at the 0.25 mg starting dose.

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring hormone released from the gut in response to food intake. By mimicking and amplifying the effects of this hormone, semaglutide acts on multiple systems in the body to support weight management.

In the early weeks of treatment, including week 3, semaglutide begins to exert its effects primarily through two key mechanisms:

• Central appetite regulation: Semaglutide acts on GLP-1 receptors in brain areas responsible for regulating hunger and satiety — including the hypothalamus and brainstem — reducing appetite and increasing feelings of fullness.

• Gastric emptying: The medication slows the rate at which the stomach empties its contents into the small intestine. This contributes to prolonged satiety after meals and is also responsible for some of the gastrointestinal side effects experienced in the early weeks.

At the 0.25 mg starting dose, these effects are present but intentionally modest. The titration schedule is designed to gradually increase receptor engagement whilst minimising side effects. Semaglutide has a half-life of approximately one week, which is why once-weekly dosing is both effective and practical.

Clinical evidence from the STEP programme of trials, which informed approval by both the EMA and MHRA for chronic weight management, demonstrated that semaglutide at the 2.4 mg maintenance dose produces clinically meaningful weight loss in adults with obesity or overweight with at least one weight-related comorbidity. The STEP trials also observed improvements in certain cardiovascular risk markers; however, the primary licensed indication for Wegovy in the UK remains chronic weight management, and patients should discuss any cardiovascular considerations with their clinician.

Dosing Schedule and NHS Titration Guidance

Week 3 falls within the 0.25 mg introductory phase; the full titration schedule runs over 17 weeks, reaching the 2.4 mg maintenance dose, and must not be accelerated without clinical guidance.

Wegovy follows a structured dose escalation schedule, which is a critical component of safe and effective treatment. According to the MHRA-approved SmPC, the standard titration schedule is as follows:

• Weeks 1–4: 0.25 mg once weekly (starting dose)

• Weeks 5–8: 0.5 mg once weekly

• Weeks 9–12: 1 mg once weekly

• Weeks 13–16: 1.7 mg once weekly

• Week 17 onwards: 2.4 mg once weekly (maintenance dose)

At week 3, patients remain on the 0.25 mg dose. This is an introductory dose intended to improve tolerability, not a therapeutic dose for weight loss. Patients should not attempt to accelerate the titration schedule without clinical guidance, as doing so significantly increases the risk of adverse gastrointestinal effects.

Flexibility within the schedule: If side effects are difficult to manage at any stage, your clinician may delay the next dose increase by up to 4 weeks to allow further adjustment. If the 2.4 mg maintenance dose is not tolerated, 1.7 mg may be used as an alternative maintenance dose. Any changes to your titration schedule should be agreed with your prescribing clinician.

Experiencing these side effects? Our pharmacists can help you navigate them →

Missed doses: If you miss a dose, administer it as soon as possible — provided there are 5 days or fewer remaining before your next scheduled dose. If more than 5 days have passed since the missed dose, skip it and take your next dose on the usual scheduled day. Do not take two doses to make up for a missed one. If you miss two or more consecutive doses, contact your prescribing clinician, as re-titration from a lower dose may be recommended to reduce the risk of gastrointestinal side effects.

Changing your injection day: If you need to change the day of the week on which you take your injection, ensure there are at least 3 days (72 hours) between the previous dose and the new injection day. After this adjustment, you can continue on the new weekly schedule.

Wegovy is administered as a subcutaneous injection once weekly, into the abdomen, thigh, or upper arm.

NHS access and eligibility: In England, Wegovy is currently available through specialist weight management services in line with NICE Technology Appraisal TA875. It is indicated for adults with a BMI of 30 kg/m² or above, or a BMI of 27 kg/m² or above with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea). Lower BMI thresholds apply for some ethnic groups, as specified in NICE guidance. Treatment is typically provided for up to 2 years within the NHS, and ongoing prescribing is contingent on demonstrating a clinically meaningful weight loss response — usually assessed after reaching the maintenance dose or at around 6 months of treatment. If less than 5% body weight has been lost by this point, your clinician will discuss whether continuing treatment is appropriate.

Wegovy should not be used during pregnancy or breastfeeding. If you are pregnant, planning a pregnancy, or breastfeeding, inform your prescribing clinician immediately. It is recommended to stop Wegovy at least 2 months before a planned pregnancy. Discuss effective contraception with your clinician if relevant.

Do not use Wegovy alongside any other GLP-1 receptor agonist or other semaglutide-containing medicine (such as Ozempic or Rybelsus). Inform your prescribing clinician of all medicines you are currently taking.

Lifestyle and Dietary Advice to Support Your Progress

Wegovy must be used alongside a reduced-calorie diet and at least 150 minutes of moderate aerobic activity per week, as required by NICE TA875 and the supporting clinical evidence.

Wegovy is not a standalone treatment. Both NICE guidance (TA875) and the clinical trial evidence underpinning its approval emphasise that the medication must be used alongside a reduced-calorie diet and increased physical activity to achieve optimal outcomes. Week 3 is an ideal time to begin embedding sustainable lifestyle habits that will support your long-term progress.

From a dietary perspective, the following principles are recommended, consistent with the NHS Eatwell Guide:

• Eat regular, balanced meals — do not skip meals, as this can worsen nausea and lead to overeating later

• Reduce portion sizes gradually — the medication will help with satiety, but mindful eating remains important

• Limit ultra-processed foods, sugary drinks, and high-fat snacks — these can exacerbate gastrointestinal side effects and undermine calorie reduction

• Prioritise protein and fibre — these nutrients support satiety and help preserve lean muscle mass during weight loss

• Stay well hydrated — aim for pale-yellow urine as a guide; if you have heart or kidney conditions, follow your clinician's specific advice on fluid intake

Regarding physical activity, the NHS recommends that adults aim for at least 150 minutes of moderate-intensity aerobic activity per week (such as brisk walking, cycling, or swimming), alongside muscle-strengthening activities on at least 2 days per week (such as resistance exercises, yoga, or carrying heavy loads). Reducing prolonged periods of sitting or inactivity is also beneficial. If you are new to exercise, starting with short daily walks and gradually increasing duration and intensity is a safe and effective approach. Full guidance is available via the NHS Physical Activity Guidelines for Adults.

Behavioural support — such as keeping a food diary, setting realistic weekly goals, or accessing NHS weight management programmes — can also significantly improve long-term adherence. If you have concerns about your diet, physical capacity, or overall progress at week 3, speak with your GP, dietitian, or prescribing clinician for personalised guidance.

Frequently Asked Questions